Source Photonics Announces New 100G ZR4 QSFP28 Transceiver for Data Center Interconnects and Routing Applications
7.12.2020 17:31:00 EET | Business Wire | Press release
Source Photonics, a leading vendor of optical connectivity products used in telecommunication systems and data communications networks, today announces the release of its new 100G ZR4 QSFP28 transceiver for 80km high-speed data center interconnects and routing applications. Leveraging the widely deployed 4 x 25G NRZ optics, 100G ZR4 QSFP28 is the latest addition to the company’s dominant 100G product lines among its leading 100/200/400G portfolio of single-mode transceivers for datacenter and routing applications.
Cloud traffic continues to drive data center growth and the industry requires cost-effective and high-bandwidth interoperable solutions. The Source Photonics 100G ZR4 QSFP28 is cost optimized and low power transceiver supporting 100G Ethernet for extended reach up to 80km transmission that provides point to point network connectivity solutions between data centers or central offices without the need to deploy either complicated, power hungry, and expensive coherent solution or legacy CFP/CFP2 interfaces. The 100G ZR4 QSFP28 alleviates the fiber shortage bottlenecks and enables hyperscale cloud operators to scale their network.
The transceiver is in QSFP28 form factor, the smallest for 100G 80km solution. It is fully compliant with the industry standard QSFP28 and related MSA described in the latest SFF-8665/8636 and digital diagnostic functions are available through an I2C interface. It also complies with IEEE 802.3 100GBASE-ZR4 related specifications. In addition, the module supports standard KR4 FEC (Forward Error Correction) baud rates which will help receive side detect and correct bit errors and improve the overall quality of the link. The 100G ZR4 QSFP28 transceiver is capable to operate over up to 80km point-to-point link without the need for optical amplification and dispersion compensation.
Source Photonics will showcase a product demonstration of the 100G ZR4 QSFP28 transceiver for 80km optical transmission in its virtual booth, in addition to live booth activities, and informative video content during the ECOC 2020 Virtual Exhibition on December 7 to 9.
Source Photonics is currently sampling its 100G ZR4 QSFP28 product, in addition to its latest 100G ER4 and 400G ER8 transceivers. Source Photonics is in full production of its other products for data center and routing applications such as 100G LR4/ER4 Lite, 100G DR1/FR1/LR1, and 400G DR4/FR4/LR4/LR8 transceivers.
For more information about Source Photonics and its product offering, please visit www.sourcephotonics.com.
About Source Photonics:
Source Photonics is a leading provider of innovative and reliable optical communications technology that enables communications and connectivity in datacenters, metro, and access networks. We add value to our customers by developing next-generation solutions that enable their growth by meeting the rapidly increasing demands of cloud infrastructure, wireless communications, routing, and fiber-to-the-premises applications worldwide. Source Photonics has key R&D and manufacturing facilities in California, Taiwan, Chengdu, and Jintan, China.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201207005591/en/
Contact information
Media Contact:
Jasmin Basal
Director, Sales and Marketing
Phone: 818-885-4202
Email: jasmin.basa@sourcephotonics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Research: Only One in Three Healthcare Organizations is Ready to Scale AI28.4.2026 16:22:00 EEST | Press release
AI is already embedded across healthcare and life sciences. Most organizations are deploying it, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428872907/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany, Spain, Saudi Arabia, and the UAE. AI is already embedded across healthcare and life sciences. Most organizations are deploying AI, and confidence in its potential is high. Yet for many, the real challenge is only just beginning. HTEC, a global AI‑first provider of software and hardware design and engineering services, today released new research based on a global survey of 253 C-level HLS executives across the United States, United Kingdom, Germany,
JPMorganChase Named First-Ever Global Banking Partner of the Olympic Games28.4.2026 16:00:00 EEST | Press release
The International Olympic Committee (IOC) and JPMorganChase today announced a landmark Worldwide Olympic Partnership, making JPMorganChase the first Global Banking Partner in Olympic history. The partnership includes the Los Angeles 2028 Olympic and Paralympic Games (LA28 Games) and the French Alps 2030 Olympic and Paralympic Winter Games. The firm has also reached an agreement with LA28 to become the Official Bank of Team USA and LA28, and a Founding Partner of the LA28 Games. The partnership reflects a shared commitment to ambition and excellence, and places athletes and communities at its core. Kirsty Coventry, President of the IOC, commented: “JPMorganChase is the first Global Partner from the banking sector in Olympic history, and we are proud to welcome them to the Worldwide Olympic Partner programme. This partnership reflects our shared values of ambition, excellence and will support the Olympic Movement and sport around the world. JPMorganChase’s global reach and expertise will
BlueSnap, Powered by Payroc, Launches Local Acquiring in New Zealand to Boost Approval Rates and Reduce Cross-Border Costs28.4.2026 16:00:00 EEST | Press release
BlueSnap, powered by Payroc, today announced the availability of local acquiring in New Zealand, expanding its global payment orchestration capabilities and enabling businesses to process transactions domestically. Local acquiring allows businesses with a legal entity in New Zealand to process payments through domestic acquiring banks rather than routing transactions cross-border. This helps increase authorization rates, reduce payment failures, and lower transaction costs, critical factors for businesses selling into the region. Why Local Acquiring in New Zealand Matters For B2B and B2C businesses operating globally, cross-border payments often lead to higher fees and lower approval rates. Building local acquiring infrastructure independently requires managing multiple bank relationships, compliance, and integrations, making it costly and complex. BlueSnap simplifies this by providing local acquiring through a single platform, allowing businesses with a legal entity in New Zealand to
Vensica Medical Receives FDA IND Clearance to Initiate Phase 2 Study of ViXe, Its Needle-Free Xeomin ® Delivery System for Overactive Bladder28.4.2026 15:42:00 EEST | Press release
Vensica Medical, a clinical-stage company developing needle-free therapeutic delivery solutions for urologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of ViXe. The study will evaluate the Vibe® ultrasound-based, needle-free drug delivery system in combination with Xeomin® (incobotulinumtoxinA) for the treatment of overactive bladder (OAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414145279/en/ Avner Geva, Cofounder, CEO (left), and Avi Eftel, Cofounder, CTO (right) Overactive bladder affects an estimated 33 million adults in the United States and is characterized by urinary urgency, frequency, and incontinence. While intravesical botulinum toxin injection is an established second-line treatment, the invasive procedure limits patient access and acceptance. The ViXe program is desi
Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care28.4.2026 15:28:00 EEST | Press release
CTIBIOTECH Announces the CTIONCOTEST ™ Project to Revolutionize Cancer Research with 3D Bioprinted Microtumors, Backed by France 2030 and Bpifrance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260428242352/en/ The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom